Agastiya Biotech
Agastiya Biotech is a clinical-stage oncology company focused on developing breakthrough cancer treatments using systems biology, immunotherapy, and quantum biophysics. Their lead molecule, AB001, is a first-in-class, tumor-agnostic, orally available therapeutic that acts as a pan-KRAS inhibitor, PD-L1 immunomodulator, and cancer stem cell dissolver. The company's proprietary P-AGI platform, a fusion of quantum biology, AI, and ancient medical knowledge, drives its molecular discovery. Agastiya Biotech has completed Phase I trials for AB001 with promising results, including no dose-limiting toxicities and demonstrated tumor shrinkage, and Phase II trials are approved in India. The company aims to develop affordable and accessible therapies, challenging conventional biotech approaches.
Agastiya Biotech
Agastiya Biotech is a clinical-stage oncology company focused on developing breakthrough cancer treatments using systems biology, immunotherapy, and quantum biophysics. Their lead molecule, AB001, is a first-in-class, tumor-agnostic, orally available therapeutic that acts as a pan-KRAS inhibitor, PD-L1 immunomodulator, and cancer stem cell dissolver. The company's proprietary P-AGI platform, a fusion of quantum biology, AI, and ancient medical knowledge, drives its molecular discovery. Agastiya Biotech has completed Phase I trials for AB001 with promising results, including no dose-limiting toxicities and demonstrated tumor shrinkage, and Phase II trials are approved in India. The company aims to develop affordable and accessible therapies, challenging conventional biotech approaches.